NCT00084071已完成3 期
Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 2,136
- 试验地点
- 149
- 主要终点
- Compare the effect of tifacogin vs placebo administration.
研究概览
简要总结
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence
- •Pneumonia of sufficient severity to require ICU admission and management
排除标准
- •Pregnancy
- •Weight over 150 kg
- •Patients at increased risk of bleeding
- •Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa
- •Treatment with heparin or anticipated need for heparin
结局指标
主要结局
Compare the effect of tifacogin vs placebo administration.
次要结局
未报告次要终点
研究者
研究点 (149)
Loading locations...
相似试验
尚未招募
不适用
Efficacy and Safety of Tofacitinib in Patients With Prurigo NodularisItchPrurigo NodularisNCT06201715Second Affiliated Hospital, School of Medicine, Zhejiang University24
招募中
不适用
Tofatib Treatment for IgG4-related DiseaseIgG4-related DiseaseNCT05625581Changhai Hospital40
终止
4 期
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive AspergillosisInvasive AspergillosisNCT02646774Astellas Pharma China, Inc.43
终止
4 期
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus SppCandidiasisAspergillosisNCT02646800Astellas Pharma China, Inc.105
Unknown
2 期
Tofacitinib Combined With Chidamide in R/R ENKTCLExtranodal NK/T-cell LymphomaNCT03598959Sichuan University20